BioSpace News Archive

Exxel Pharma announced that Soren Mogelsvang, PhD, President and Chief Executive Officer and Daniele Piomelli, PhD, MD, Chief Scientific Officer of Exxel, will participate in the Virtual Investor Summer Spotlight Series on Tuesday, July 11, 2023 at 1:00 PM ET.

Arbutus Biopharma Corporation announced the appointment of Dr. Karen Sims as Chief Medical Officer and Mr. Christopher Naftzger as General Counsel and Chief Compliance Officer.

Haemonetics Corporation announced that the Company intends to publish first quarter fiscal year 2024 financial results at 6:00 am ET on Tuesday, August 8, 2023.

Adaptive Biotechnologies Corporation announced it will report financial results for the second quarter 2023 after market close on Wednesday, August 2, 2023.

Viridian Therapeutics, Inc. announced positive preliminary data from its ongoing Phase 1/2 clinical trial of VRDN-001, an investigational full antagonist antibody to the insulin-like growth factor 1 receptor, in patients with chronic thyroid eye disease.

Alphyn Biologics announced new data from the first cohort of its Phase 2a clinical trial program of AB-101a, a first-in-class topical candidate for treating atopic dermatitis in children ages 2 through adult.

Johnson & Johnson will participate in the UBS MedTech, Tools and Genomics Summit on Tuesday, August 15th, at the Waldorf Astoria Monarch Beach Resort & Club in Dana Point, CA.

Iovance Biotherapeutics, Inc., a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte therapies for patients with cancer, announced the pricing of an underwritten public offering of 20,000,000 shares of its common stock at a public offering price of $7.50 per share.

The March of Dimes National Board of Trustees announced the appointment of Dr. Elizabeth Cherot as the organization’s new President and Chief Executive Officer, effective July 17.

Cellinfinity Bio announced the publication of MAJESTIC, a technology that efficiently and with high cell health introduces genes into human genome, independent of CRISPR and lentiviral methods.